Special Issue "CNS-Drugs and Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 30 June 2013
Prof. Dr. Michael Kassiou
School of Chemistry, Brain and Mind Research Institute, The University of Sydney, NSW, 2006, Australia
Interests: CNS active molecules; neuroprotective agents; medicinal chemistry and drug discovery; structure-activity relationships of CNS bioactive molecules; rationale CNS drug design and evaluation; heterocyclic chemistry
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
Article: A Potent (R)-alpha-bis-lipoyl Derivative Containing 8-Hydroxyquinoline Scaffold: Synthesis and Biological Evaluation of Its Neuroprotective Capabilities in SH-SY5Y Human Neuroblastoma Cells
Pharmaceuticals 2013, 6(1), 54-69; doi:10.3390/ph6010054
Received: 6 December 2012; in revised form: 18 December 2012 / Accepted: 31 December 2012 / Published: 7 January 2013| Download PDF Full-text (887 KB) | Download XML Full-text
Last update: 19 November 2012